



Talecris Biotherapeutics
Research Triangle Park, NC
27709 USA
Tel. 919.316.6316
www.talecris.com

News release

Talecris Biotherapeutics to Acquire Plasma Collection Centers

Centers Acquired from International BioResources, LLC to Form Talecris Plasma Resources, Secure Future Supply of Talecris Products for Patient Communities

RESEARCH TRIANGLE PARK, N.C. (November 6, 2006) — Talecris Plasma Resources, a wholly owned subsidiary of Talecris Biotherapeutics, Inc. , today announced it has signed a purchase acquisition agreement with International BioResources, LLC (IBR) to acquire the majority of IBR’s plasma sourcing centers that are geographically distributed across 21 states in the U.S., employing nearly 1,000 people. Talecris Plasma Resources will incorporate the 58 centers acquired from IBR into their expansion plans in plasma sourcing. Of the 58 centers, 21 are licensed, 12 are operating and awaiting FDA approval for licensure, and 25 are under various stages of development. Financial terms of the deal were not disclosed.

“These are exciting times for Talecris, and this acquisition represents an important strategic step toward Talecris’ planned successful growth,” said Alberto Martinez, M.D., President and CEO, Talecris Biotherapeutics. “With the people and resources of IBR, we are better positioned to further ensure a reliable supply of our life-saving critical care products, and meet our customers’ needs well into the future.”

Talecris expects to complete the acquisition within the next 30 to 60 days, subject to a series of regulatory approvals. Talecris plans to integrate the associated IBR employees into the Talecris organization as quickly as possible, and will augment the acquired staff with support from its quality, compliance, and other business units to accelerate the growth and development of the acquired platform.

– more –

Talecris has been reviewing strategic options to meet the ever-increasing demands for its plasma-derived therapeutic protein products, the manufacture of which relies on human plasma as source material. Talecris produces therapies for chronic rare diseases such as alpha-1 antitrypsin deficiency (alpha-1), primary humoral immunodeficiency disease (PI), and hemophilia. The acquisition of most of the IBR assets aims to streamline the Talecris supply chain, further ensuring reliable supplies of the safest possible products.

International BioResources, LLC is headquartered in Lafayette, LA.

Contact:

Lacy McMahan

Tel.: 919.316.6316, Fax: 919.316.6673

E-mail: lacy.mcmahan@talecris.com

About Talecris Biotherapeutics: *Inspiration. Dedication. Innovation.*

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.

Talecris, which earned revenues exceeding \$1 billion through the year ending June 30, 2006, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 2,000 talented people worldwide.

To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.

###